Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS6660034 B1
Tipo de publicaciónConcesión
Número de solicitudUS 09/846,498
Fecha de publicación9 Dic 2003
Fecha de presentación30 Abr 2001
Fecha de prioridad30 Abr 2001
TarifaPagadas
También publicado comoUS7625593, US7867549, US20040071861, US20100047315
Número de publicación09846498, 846498, US 6660034 B1, US 6660034B1, US-B1-6660034, US6660034 B1, US6660034B1
InventoresEvgenia Mandrusov, Paul Consigny, Syed Faiyaz Ahmed Hossainy, Dary Mirzaee
Cesionario originalAdvanced Cardiovascular Systems, Inc.
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Stent for increasing blood flow to ischemic tissues and a method of using the same
US 6660034 B1
Resumen
An implantable stent for a vessel includes a tubular body having an inner and outer surface. The inner and outer surfaces are coated with therapeutic substances. The therapeutic substance of the inner surface, such as an angiogenic substance, can be released downstream in the lumen. The therapeutic substance of the outer surface can be applied to the inner surface of the vessel.
Imágenes(3)
Previous page
Next page
Reclamaciones(28)
What is claimed is:
1. A stent, comprising:
a tubular body having an outer surface configured to contact the wall of a vessel and an inner surface;
a first coating supported by the inner surface and containing an angiogenic substance, the first coating configured to release the angiogenic substance in the vessel; and
a second coating supported by the outer surface and containing a therapeutic substance capable of inhibiting migration or proliferation of smooth muscle cells, the second coating configured to apply the therapeutic substance to the wall of the vessel,
wherein the outer surface is free from the first coating containing the angiogenic substance and the inner surface is free from the second coating containing the therapeutic substance.
2. The stent of claim 1, wherein the angiogenic substance is selected from a group of vascular endothelial growth factor, fibroblast growth factors, monocyte chemoattractant protein 1, transforming growth factor beta, transforming growth factor alpha, lipid factors, hypoxia-inducible factor 1-alpha, PR39, del 1, nicotine, insulin-like growth factors, placental growth factor, hepatocyte growth factor, estrogen, follistatin, proliferin, cytokines, tumor necrosis factor, erythropoietin, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, angiogenin, hormones, and genes that encode such substances.
3. The stent of claim 1, wherein the angiogenic substance is a vascular endothelial growth factor.
4. The stent of claim 1, wherein the angiogenic substance is a fibroblast growth factor.
5. The stent of claim 1, wherein the angiogenic substance is monocyte chemoattractant protein 1.
6. The stent of claim 1, wherein the angiogenic substance is a transforming growth factor beta.
7. The stent of claim 1, wherein the angiogenic substance is a transforming growth factor alpha.
8. The stent of claim 1, wherein the angiogenic substance is a lipid factor.
9. The stent of claim 1, wherein the angiogenic substance is hypoxia-inducible factor 1-alpha.
10. The stent of claim 1, wherein the angiogenic substance is PR39.
11. The stent of claim 1, wherein the angiogenic substance is del 1.
12. The stent of claim 1, wherein the angiogenic substance is nicotine.
13. The stent of claim 1, wherein the angiogenic substance is an insulin-like growth factor.
14. The stent of claim 1, wherein the angiogenic substance is a placental growth factor.
15. The stent of claim 1, wherein the angiogenic substance is a hepatocyte growth factor.
16. The stent of claim 1, wherein the angiogenic substance is estrogen.
17. The stent of claim 1, wherein the angiogenic substance is follistatin.
18. The stent of claim 1, wherein the angiogenic substance is proliferin.
19. The stent of claim 1, wherein the angiogenic substance is a cytokine.
20. The stent of claim 1, wherein the angiogenic substance is a tumor necrosis factor.
21. The stent of claim 1, wherein the angiogenic substance is erythopoietin.
22. The stent of claim 1, wherein the angiogenic substance is a granulocyte colony-stimulating factor.
23. The stent of claim 1, wherein the angiogenic substance is a granulocyte macrophage colony-stimulating factor.
24. The stent of claim 1, wherein the angiogenic substance is angiogenin.
25. A stent for implanting in a blood vessel comprising a tubular structure having an inner surface and an outer surface, comprising:
a first therapeutic substance carried by the inner surface, the first therapeutic substance configured to be released downstream with the flow of blood; and
a second therapeutic substance, different from the first therapeutic substance, the second therapeutic substance carried by the outer surface and configured to be delivered to the blood vessel wall,
wherein the first therapeutic substance facilitates therapeutic angiogenesis and the second therapeutic substance inhibits migration or proliferation of smooth muscle cells,
wherein the outer surface is free from the first therapeutic substance and wherein the inner surface is free from the second therapeutic substance.
26. The stent of claim 25, wherein the inner surface has a first polymeric coating deposited thereon for the sustained release of the first therapeutic substance and wherein the outer surface has a second polymeric coating deposited thereon for the sustained release of the second therapeutic substance.
27. The stent of claim 25, wherein the first therapeutic substance is selected from a group of vascular endothelial growth factor, fibroblast growth factors, monocyte chemoattractant protein 1, transforming growth factor beta, transforming growth factor alpha, lipid factors, hypoxia-inducible factor 1-alpha, PR39, del 1, nicotine, insulin-like growth factors, placental growth factor, hepatocyte growth factor, estrogen, follistatin, proliferin, cytokines, tumor necrosis factor, erythropoietin, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, angiogenin, hormones, and genes that encode such substances.
28. The stent of claim 25, wherein the second therapeutic substance is selected from a group ofactinomycin D, docetaxel and paclitaxel.
Descripción
BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to implantable medical devices, such as stents, and a method of resolving ischemia by inducing formation of new blood vessels through angiogenesis and arteriogenesis.

2. Description of the Background

A major component of morbidity and mortality attributable to cardiovascular disease occurs as a consequence of the partial or complete blockage of vessels carrying blood in the coronary and/or peripheral vasculature. When such vessels are occluded, various complications may result from death of tissue previously nourished by the occluded vessels or inability of the occluded vessels to transport sufficient blood supply to regions requiring high blood consumption and accompanying nutrients.

Blood vessel occlusions are commonly treated by mechanically enhancing blood flow in the affected vessels. Such mechanical enhancements are often provided by employing surgical techniques that attach natural or synthetic conduits proximal and distal to the areas of occlusion, thereby providing bypass grafts, or revascularization by various means to physically enlarge the vascular lumen at the site of occlusion. These revascularization procedures involve such devices as balloons, endovascular knives (atherectomy), and endovascular drills. The surgical approach is accompanied by significant morbidity and even mortality, while the angioplasty-type processes are complicated by recurrent stenoses in many cases.

In some individuals, blood vessel occlusion is partially compensated by the natural process of therapeutic angiogenesis, in which new vessels are formed to replace the function of the impaired vessels. These new conduits may facilitate restoration of blood flow to the deprived tissue, thereby constituting “natural bypasses” around the occluded vessels. However, some individuals are unable to generate sufficient new vessels to adequately compensate for the diminished blood flow caused by cardiovascular disease. Accordingly, it would be desirable to provide methods and systems for delivering agents to help stimulate the natural process of therapeutic angiogenesis in occluded coronary and peripheral arteries in order to treat ischemia.

SUMMARY

A stent is provided. The stent includes a tubular body having an outer surface for contacting the wall of a vessel and an inner surface. The stent also includes a first coating supported by the inner surface and containing an angiogenic substance for the release of the angiogenic substance in the vessel. In addition, the stent includes a second coating supported by the outer surface and containing a therapeutic substance for applying the therapeutic substance to the wall of the vessel.

In some embodiments, the therapeutic substance is selected from antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antioxidant, and anti-migratory substances, inhibitors of matrix synthesis, and combinations thereof.

Also provided is a stent, which includes a tubular structure having an inner surface and an outer surface, for implanting in a blood vessel. The stent includes a first therapeutic substance carried by the inner surface for being released downstream with the flow of blood and a second therapeutic substance, which is different from the first therapeutic substance, carried by the outer surface for application to the blood vessel wall. The first therapeutic substance facilitates therapeutic angiogenesis, and the second therapeutic substance inhibits migration or proliferation of smooth muscle cells.

In one embodiment, the inner surface of the stent includes a plurality of cavities for releasing the first therapeutic substance when exposed to the flow of blood. In another embodiment, the inner surface includes a plurality of cavities for releasing the first therapeutic substance when exposed to the flow of blood, and the outer surface includes a plurality of cavities for applying the second therapeutic substance to the blood vessel wall.

A method for increasing blood flow to ischemic tissues located downstream from an occluded region in a blood vessel is also provided. The method includes implanting a stent in the blood vessel at a location upstream from the ischemic tissues. The stent has an inner surface carrying an angiogenic substance.

In one embodiment, the stent is positioned at a location upstream of the occluded region. In another embodiment, the stent is positioned across at least a portion of the occluded region.

In yet another embodiment, the stent additionally includes a coating disposed on the outer surface of the stent. The coating includes a therapeutic substance. In another embodiment, the stent includes cavities on the outer surface containing a therapeutic substance.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A illustrates a stent.

FIG. 1B illustrates an end view of the stent of FIG. 1A.

FIG. 2 illustrates the stent of FIG. 1B having a first coating containing an angiogenic substance formed on the inner surface.

FIG. 3 illustrates the stent of FIG. 2 having a second coating formed on the outer surface.

FIG. 4A is the region 4A of the stent of FIG. 1A illustrating a therapeutic substance in cavities formed within the outer surface.

FIG. 4B illustrates the stent of FIG. 4A taken along line 4B—4B in accordance with an embodiment in which the therapeutic substances are releasably contained in cavities within the inner and outer surfaces, respectively.

FIGS. 5A-5D illustrate a method for increasing blood flow to ischemic tissue in accordance with several embodiments of the present invention.

FIG. 6 illustrates a method for increasing blood flow to ischemic tissue in accordance with another embodiment of the present invention.

DETAILED DESCRIPTION

Angiogenic substances should be understood to broadly include any proteins, peptides, and small molecules as well as cells, genes, and other substances that promote, stimulate or cause therapeutic angiogenesis. One of ordinary skill in the art is familiar with methods used to determine the angiogenic or arteriogenic activity of a substance, examples of which include the use of rabbit hind limb ischemia models and pig ameroid constrictor models. Representative examples of angiogenic substances include vascular endothelial growth factor (VEGF) in any of its multiple isoforms, fibroblast growth factors, monocyte chemoattractant protein 1 (MCP-1), transforming growth factor beta (TGF-beta) in any of its multiple isoforms, transforming growth factor alpha (TGF-alpha), lipid factors, hypoxia-inducible factor 1-alpha (HIF-1-alpha), PR39, del 1, nicotine, insulin-like growth factors, placental growth factor (PIGF), hepatocyte growth factor (HGF), estrogen, follistatin, proliferin, prostaglandin E1, prostaglandin E2, cytokines, tumor necrosis factor (TNF-alpha), erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), angiogenin, hormones, and genes that encode such substances.

VEGF, a 46 kD protein, has isoforms containing 121, 165, 189, and 206 amino acids. VEGF is a heparin-binding protein that is mitogenic for endothelial cells only. This mitogen is also known as vascular permeability factor and will induce vessel leakage at doses higher than those required for angiogenic response. VEGF has been shown to induce functionally significant angiogenesis in the acute and chronic coronary ischemia models in pigs and dogs. This protein was tested in phase II clinical trials and was shown to be safe at the administered doses.

The heparin-binding fibroblast growth factor (FGF) family includes ten currently identified mitogens and four additional homologs of unknown function. FGF-2, also referred to as FGF-beta, is a 16.5 kD, 146 amino acid protein. FGF-2 is a pluripotent mitogen capable of stimulating migration and proliferation of a variety of cell types including fibroblasts, macrophages, smooth muscle cells and endothelial cells. FGF-2 can also stimulate endothelial production of various proteases including plasminogen activator and matrix metalloproteinases, induce significant vasodilation through stimulation of nitric oxide release, and promote chemotaxis. FGF-2 is present in the normal myocardium and its expression is potentiated by hypoxia or hemodynamic stress. This protein has been shown to induce functionally significant angiogenesis in the acute and chronic coronary ischemia models in pigs and dogs. FGF-2 was tested in phase II clinical trials and was shown to be safe at the administered doses. FGF-1, also referred to as FGF-alpha, is an unstable form of fibroblast growth factor that has similar action as FGF-2. However, FGF-1is 30-100 times less potent than FGF-2.

MCP-1 is produced by shear stress-activated endothelium. Monocytes transmigrate through the vessel wall of proliferating collateral arteries and produce MCP-1, resulting in monocyte homing and acceleration of the natural process of collateral growth by degradation of the basement membrane, proliferation of smooth muscle cells and endothelial cells, and enlargement of the pre-existing vessel.

TGF-beta exists in at least five isoforms, each of which is encoded by a different gene. TGF-beta directly induces proliferation, migration and/or differentiation of endothelial cells. It has been reported that TGF-beta signaling may regulate VEGF expression in cardiac myocytes. (Zheng, et al., “Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta,” Am J. Physiol Heart Circ. Physiol, 280(2):H909-17 (February 2001).)

TGF-alpha directly induces proliferation, migration and/or differentiation of endothelial cells.

Lipid factors include spingosine 1-phosphate (SIP), which is stored in platelet granules and is released upon platelet activation, as well as lysophasphatidate (LPA) and phosphatidic acid (PA). SIP, LPA, and PA bind to endothelial differentiation gene receptors, a novel family of G-protein-coupled receptors present in endothelial cells. When stimulated, these receptors activate pathways that ultimately result in endothelial cell responses associated with angiogenesis including the liberation of endothelial cells from established monolayers, chemotactic migration, and proliferation.

HIF-1-alpha has been shown in cell culture to be a transcriptional activator for VEGF. HIF-1-alpha has been selectively expressed in areas of ischemia or infarction, but not in myocardium remote to ischemic or infarcted areas. The presence of HIF-1-alpha MRNA, and subsequently the presence of VEGF mRNA, in the heart tissue of patients with infarction is said to indicate that HIF-1-alpha contributes to limitation of infarct size by promoting angiogenesis and vascular remodeling, and that it does so by increasing steady-state levels of VEGF mRNA.

PR39, a macrophage-derived peptide, inhibits the ubiquitin-proteasome-dependent degradation of HIF-1-alpha protein, resulting in accelerated formation of vascular structures in vitro and increased myocardial vasculature in mice. Coronary flow studies in mice have demonstrated that PR39-induced angiogenesis resulted in the production of functional blood vessels. Such findings indicate that PR39 and related compounds can be used as potent inductors of angiogenesis and that selective inhibition of HIF-1-alpha degradation may underlie the mechanism of inflammation-induced angiogenesis. (Li, et al., “A peptide regulator of angiogenesis,” Nat Med. 6(1), 6(3), pgs. 49-55 (January and March 2000))

Del 1, an extracellular matrix protein, encodes three Notch-like epidermal growth factor repeats: an RGD motif, and two discoidin domains. Del 1 is expressed in an endothelial cell-restricted pattern during early development. In some studies, recombinant baculovirus Del 1 protein was shown to promote alphavbeta3-dependent endothelial cell attachment and migration. Attachment of endothelial cells to Del 1 was associated with clustering of alphavbeta3, the formation of focal complexes, and recruitment of talin and vinculin into these complexes. These events were shown to be associated with phosphorylation of proteins in the focal complexes, including the time-dependent phosphorylation of p125(FAK), MAPK, and Shc. When recombinant Del 1 was evaluated in an in-ovo chick chorioallantoic membrane assay, it was found to have potent angiogenic activity. This angiogenic activity was inhibited by a monoclonal antibody directed against alphavbeta3, and an RAD mutant Del 1 protein was inactive. Thus, Del 1 has been indicated to provide a unique autocrine angiogenic pathway for the embryonic endothelium, and this function is mediated in part by productive ligation of integrin alphabeta3. (Penta, et al., “Del 1 induces integrin signaling and angiogenesis by ligation of alphaVbeta3,” J. Biol Chem, 16; 274 (April 1999).)

Nicotine, via stimulation of nicotinic receptors, has been shown to enhance angiogenesis and may stimulate tumor growth in part by enhancing tumor vascularity. (Heeschen, et al., “Nicotine Stimulates Tumor Angiogenesis,” Stanford University, Stanford, Calif., (2001).)

Two different insulin-like growth factors have been described, IGF-1 and IGF-2. The two factors are encoded by two different genes, which are expressed differentially in different tissues and at different times of development. IGF-1 is a 150 kD peptide that is synthesized by many cell types, including smooth muscle cells. This peptide stimulates migration and tube formation by vascular endothelial cells as wells as migration and proliferation of smooth muscle cells, which are important steps in the angiogenesis process.

“Therapeutic angiogenesis” refers to the processes of causing or inducing angiogenesis and arteriogenesis.

“Angiogenesis” is defined as promotion or causation of the formation of new blood vessels.

“Arteriogenesis” is the formation of collateral vessels, which typically occurs in a non-ischemic region of a vessel. The collateral vessels allow blood to flow from a well-perfused region of the vessel into the ischemic region.

“Ischemia” is defined as localized reduction in blood flow caused by narrowing or occlusion of one or more vessels, such as coronary arteries or their branches, most often through thrombosis or via deposits of fat, connective tissue, calcification of the walls, or restenosis caused by the abnormal migration and proliferation of smooth muscle cells.

“Occlusion” is defined as the total or partial obstruction of blood flow through a vessel.

“Smooth muscle cells” include those cells derived from the medial and adventitial layers of the vessel that migrate and proliferate in intimal vascular sites.

“Migration” of smooth muscle cells means movement of these cells in vivo from the medial layers of a vessel into the intima, such as may also be studied in vitro by following the motion of a cell from one location to another, e.g., using time-lapse cinematography or a video recorder and manual counting of smooth muscle cell migration out of a defined area in the tissue culture over time.

“Proliferation” of smooth muscle cells means increase in cell number.

“Abnormal” proliferation means division, growth or migration of cells occurring more rapidly or to a significantly greater extent than typically occurs in a normally functioning cell of the same type, i.e., hyper-proliferation.

“Inhibiting” cellular activity means reducing, delaying or eliminating smooth muscle cell migration and/or proliferation that causes hyperplasia, restenosis, and vascular occlusions, particularly following biologically or mechanically mediated vascular injury or trauma or under conditions that would predispose a mammal to suffer such a vascular injury or trauma.

A stent is broadly defined to include any inter- or intra-luminal device used for the release of an active ingredient and/or for upholding the luminal patency. Examples of stents include self-expandable stents, balloon-expandable stents, and stent-grafts. The stent can be made of a metallic material or an alloy such as, but not limited to, stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. The stent can also be made from bioabsorbable or biostable polymers.

The stent can be coated with a polymeric material for the delivery of the angiogenic substance alone or in combination with a therapeutic substance. “Polymer,” “poly,” and “polymeric” are defined as compounds that are the product of a polymerization reaction and are inclusive of homopolymers, copolymers, terpolymers etc., including random, alternating, block, and graft variations thereof. Representative examples of polymers that can be used with the embodiments of the present invention include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(hydroxyvalerate); poly(L-lactic acid); polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxalates; polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; polyurethanes; rayon; rayon-triacetate; cellulose; cellulose acetate; cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose.

The Figures have not been drawn to scale, and the dimensions such as depth and thickness of the various regions and layers have been over or under emphasized for illustrative purposes. Referring to FIGS. 1A and 1B, a stent 10 is formed from a plurality of struts 12. Struts 12 are separated by gaps 14 and may be interconnected by connecting elements 16. Struts 12 can be connected in any suitable configuration and pattern. Stent 10 is illustrated having an outer surface 18 (tissue-contacting surface) and an inner surface 20 (blood-contacting surface). A hollow, central bore 22 extends longitudinally from a first end 24 to a second end 26 of stent 10.

FIG. 2 illustrates stent 10 having a first coating 28 formed on inner surface 20. First coating 28 can be of any suitable thickness. The thickness of first coating 28 can be from about 0.1-15 microns, more narrowly from about 3 microns to about 8 microns. By way of example, first coating 28 can have a thickness of about 5 microns.

First coating 28 can be made from a polymeric material containing an angiogenic substance. First coating 28 can be formed by any suitable method, such as by applying a first solution containing a dissolved mixture of a first solvent, a first polymer, and the angiogenic substance onto inner surface 20 and allowing the first solvent to evaporate from the first solution. Examples of suitable solvents include dimethylsulfoxide (DMSO), chloroform, acetone, water (buffered saline), xylene, methanol, ethanol, 1-propanol, tetrahydrofuran, 1-butanone, dimethylformamide, dimethylacetamide, cyclohexanone, ethyl acetate, methylethylketone, propylene glycol monomethylether, isopropanol, isopropanol admixed with water, N-methyl pyrrolidinone, toluene, and combinations thereof.

The first solution can be deposited onto inner surface 20 in any suitable manner capable of allowing the first solution to be applied to inner surface 20 without exposure of outer surface 18 to the first solution. For example, outer surface 18 can be covered by a removable sheath during application of the first solution, allowing the first solution to coat only inner surface 20.

The dosage or concentration of the angiogenic substance required to produce a therapeutic effect should be less than the level at which the angiogenic substance produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the angiogenic substance required can depend upon factors such as the particular circumstances of the patient; the time over which the angiogenic substance administered resides at the treatment site; and if other bioactive substances are employed, the nature and type of the substance or combination of substances. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.

FIG. 3 illustrates stent 10 coated in accordance with another embodiment of the present invention. In addition to first coating 28 containing an angiogenic substance on inner surface 20, a second coating 32 containing a therapeutic substance is formed on outer surface 18 of stent 10. Second coating 32 can be of any suitable thickness. The thickness of second coating 32 can be from about 0.1-15 microns, more narrowly from about 3 microns to about 8 microns. By way of example, second coating 32 can have a thickness of about 4 microns.

Second coating 32 can be formed on outer surface 18 prior to or subsequent to the formation of first coating 28 on inner surface 20. Stent 10 can be temporarily mounted on a conventional mandrel such that the mandrel fits within hollow bore 22 and against inner surface 20 or first coating 28. Stent 10 can then be immersed in or sprayed with a polymer-solvent composition containing a therapeutic substance to form second coating 32.

The therapeutic substance in second coating 32 can be an angiogenic substance that is the same as or different than the angiogenic substance contained within first coating 28. Alternatively, the therapeutic substance in second coating 32 can be any active ingredient capable of exerting a therapeutic or prophylactic effect in the practice of the present invention. The therapeutic substance can also be for enhancing wound healing in a vascular site and improving the structural and elastic properties of the vascular site. More particularly, the therapeutic substance should be for inhibiting abnormal migration and/or proliferation of smooth muscle cells for the treatment of restenosis. Examples of such substances include antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antioxidant and anti-migratory substances, inhibitors of matrix synthesis, and combinations thereof.

A suitable example of an antiproliferative substance is actinomycin D, or derivatives and analogs thereof. Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. Examples of suitable antineoplastics include paclitaxel and docetaxel. Examples of suitable antiplatelets, anticoagulants, antifibrins, and antithrombins include sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein lIb/Illa platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor (available from Biogen), and 7E3B® (an antiplatelet drug from Centocore). Examples of suitable antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, and mitomycin. Examples of suitable cytostatic or antiproliferative agents include angiopeptin (a somatostatin analog from Ibsen), angiotensin converting enzyme inhibitors such as CAPTOPRIL (available from Squibb), CILAZAPRIL (available from Hoffman-LaRoche), or LISINOPRIL (available from Merck); calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonist, LOVASTATIN (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck), monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available form Glazo), Surmin (a PDGF antagonist), serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, and dexamethasone.

FIGS. 4A-4B illustrate stent 10 in accordance with another embodiment of the present invention. In lieu of, or in addition to, coating outer surface 18 and inner surface 20 with polymeric coatings, cavities 34 a and/or 34 b are disposed in surfaces 18 and 20, respectively, for releasably containing the therapeutic and/or angiogenic substances. Cavities 34 a within outer surface 18 contain a therapeutic substance, as indicated by dotted region 36, and cavities 34 b within inner surface 20 contain an angiogenic substance, as indicated by dotted region 38. The substances can be deposited into the cavities in a solid form or contained in a polymeric matrix for reducing the rate of release.

Using the Embodiments of the Device to Treat Ischemia

FIGS. 5A-5D illustrate the use of stent 10 in a vessel 40 through which blood flows in a downstream direction 42. Vessel 40 is illustrated having an occlusion 44 and an ischemic region 46 downstream of occlusion 44. Referring to FIG. 5A, stent 10, carrying an angiogenic substance within a first coating on inner surface 20 and/or in cavities 34 b within inner surface 20, is positioned within vessel 40 at a location that is upstream of, or proximal to, occlusion 44. In one such embodiment, stent 10 is made of a bioabsorbable material. As indicated by dashed arrows 48 in FIG. 5B, the angiogenic substance is released from inner surface 20 into blood flowing through central bore 22 in the downstream direction 42. The angiogenic substance, as illustrated by dotted region 38 in FIG. 5C, emerges from the distal end of stent 10, flowing in the downstream direction 42 toward and through occlusion 44.

Referring to FIG. 5D, the released angiogenic substance can stimulate or promote formation of one or more collateral vessels 50 downstream of, or distal to, the site of implantation of stent 10. Such arteriogenesis enables circumvention of occlusion 44 by providing an alternate, less resistant pathway through which blood may travel. Accordingly, blood flow to ischemic region 46 is increased as blood travels through collateral vessel 50 as well as through occluded vessel 40.

The angiogenic substance can also stimulate angiogenesis downstream of the site of implantation of stent 10. Microvessels can provide blood with an increased number of pathways. Blood flow to ischemic region 46 can be therefore increased in primarily two ways. First, the increased number of pathways through which blood may flow can result in an increase in the amount of blood that reaches ischemic region 46. Second, an increased capillary bed in the ischemic region will allow more efficient distribution of blood in this zone and will result in a decreased overall resistance of this bed. Such a decrease in pressure may allow more blood to travel through vessel 40 due to a lower resistance therein.

Stent 10 can optionally provide for the release of a therapeutic substance carried within second coating 32 on outer surface 18 and/or in cavities 34 a within outer surface 18, as illustrated by arrows 52. In an embodiment in which the therapeutic substance is a second angiogenic substance, the second angiogenic. substance can stimulate formation of additional collateral vessels 50 as well as additional microvessels. Alternatively, in an embodiment in which the therapeutic substance is a non-angiogenic substance, the therapeutic substance can otherwise act at the site of implantation of stent 10 for the treatment of vessel 40. By way of example, in an embodiment in which the therapeutic substance is an anti-proliferative substance, e.g., actinomycin D, the substance can help inhibit abnormal migration or proliferation of smooth muscle cells at the site at which stent 10 was implanted.

Referring to FIG. 6, stent 10 may be used to mechanically dilate vessel 40 in addition to providing treatment via the release of an angiogenic substance and an optional second therapeutic substance. Stent 10 can be positioned within vessel 40 such that stent 10 extends at least partially through occlusion 44. Stent 10 can physically hold open the wall of vessel 40 at the site of implantation. Accordingly, blood can flow more freely through the previously-occluded portion of vessel 40 in the downstream direction 42 toward ischemic region 46.

While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US6071305 *24 Nov 19976 Jun 2000Alza CorporationDirectional drug delivery stent and method of use
US6206914 *31 Ago 199827 Mar 2001Medtronic, Inc.Implantable system with drug-eluting cells for on-demand local drug delivery
US6299604 *20 Ago 19999 Oct 2001Cook IncorporatedCoated implantable medical device
US6334872 *7 Jul 19971 Ene 2002Organogenesis Inc.Method for treating diseased or damaged organs
US6379379 *13 Ago 199930 Abr 2002Scimed Life Systems, Inc.Stent with smooth ends
US6391052 *29 Oct 199721 May 2002Scimed Life Systems, Inc.Stent with collagen
US6395023 *11 May 199928 May 2002Endovasc Ltd., Inc.Prosthesis with biodegradable surface coating and method for making same
US6436135 *24 Oct 197420 Ago 2002David GoldfarbProsthetic vascular graft
Otras citas
Referencia
1A. Helisch, et al., "Angiogenesis and arteriogenesis-not yet for prescription," Z Kardiol, 89, pp. 239-244 (2000).
2A. Helisch, et al., "Angiogenesis and arteriogenesis—not yet for prescription," Z Kardiol, 89, pp. 239-244 (2000).
3B.D. Klugherz, et al., "Gene delivery from a DNA controlled-release stent in porcine coronary arteries," Nature Biotechnology, vol. 18, pp. 1181-1184 (Nov. 2000).
4Heeschen et al., Nicotine Stimulates Tumor Angiogenesis, Abstract, American College of Cardiology 50th Annual Scientific Session, Stanford, California, Mar. 18, 2001.
5I. Buschmann, et al., "Arteriogenesis Versus Angiogenesis: Two Mechanisms of Vessel Growth," News Physiol. Sci., vol. 14, pp. 121-125 (Jun. 1999).
6J. Li, et al., "PR39, a peptide regulator of angiogenesis," Nature Medicine, vol. 6, No. 1, pp. 49-55 (Jan. 2000).
7M. Simons, et al., "Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus. An Expert Panel Summary," Circulation, pp. 1-14, (Sep. 2000).
8N. Kipshidze, et al., "Therapeutic Angiogenesis for Critical Limb Ischemia to Limit or Avoid Amputation," The Journal of Invasive Cardiology, vol. 11, No. 1, pp. 25-28 (Jan. 1999).
9Penta et al., Del1 Induces Integrin Signaling and Angiogenesis by Ligation of alphaVbeta3, J. Biolog. Chem. 274(16):11101-11109 (Apr. 16, 1999).
10Penta et al., Del1 Induces Integrin Signaling and Angiogenesis by Ligation of αVβ3, J. Biolog. Chem. 274(16):11101-11109 (Apr. 16, 1999).
11W. Zheng, et al., "Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta," AJP-Heart and Circulatory Physiology, vol. 280, Issue 2, H909-H917, (Feb. 2001).
12W. Zheng, et al., "Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta," AJP—Heart and Circulatory Physiology, vol. 280, Issue 2, H909-H917, (Feb. 2001).
13W.D. Ito, et al., "Monocyte Chemotactic Protein-1 Increases Collateral and Peripheral Conductance After Femoral Artery Occlusion," Circulation Research, vol. 80, No. 6, pp. 829-837 (Jun. 1997).
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US6852122 *23 Ene 20038 Feb 2005Cordis CorporationCoated endovascular AAA device
US7070613 *4 Ene 20024 Jul 2006Boston Scientific Scimed, Inc.Non-compliant balloon with compliant top-layer to protect coated stents during expansion
US7135039 *6 Mar 200114 Nov 2006Boston Scientific Scimed, Inc.Intraluminar perforated radially expandable drug delivery prosthesis and a method for the production thereof
US7208010 *7 Sep 200124 Abr 2007Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US740217030 Dic 200322 Jul 2008Scimed Life Systems, Inc.Crimp and weld wire connection
US764872519 May 200619 Ene 2010Advanced Cardiovascular Systems, Inc.Clamp mandrel fixture and a method of using the same to minimize coating defects
US764872726 Ago 200419 Ene 2010Advanced Cardiovascular Systems, Inc.Methods for manufacturing a coated stent-balloon assembly
US768266930 Jul 200123 Mar 2010Advanced Cardiovascular Systems, Inc.Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
US769140117 May 20056 Abr 2010Advanced Cardiovascular Systems, Inc.Poly(butylmethacrylate) and rapamycin coated stent
US76998892 May 200820 Abr 2010Advanced Cardiovascular Systems, Inc.Poly(ester amide) block copolymers
US77136373 Mar 200611 May 2010Advanced Cardiovascular Systems, Inc.Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US772266119 Dic 200725 May 2010Boston Scientific Scimed, Inc.Stent
US7727221 *27 Jun 20021 Jun 2010Cardiac Pacemakers Inc.Method and device for electrochemical formation of therapeutic species in vivo
US7732190 *31 Jul 20068 Jun 2010Advanced Cardiovascular Systems, Inc.Modified two-component gelation systems, methods of use and methods of manufacture
US773544928 Jul 200515 Jun 2010Advanced Cardiovascular Systems, Inc.Stent fixture having rounded support structures and method for use thereof
US7744644 *19 Mar 200429 Jun 2010Boston Scientific Scimed, Inc.Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release
US77492637 Ene 20086 Jul 2010Abbott Cardiovascular Systems Inc.Poly(ester amide) filler blends for modulation of coating properties
US775888031 Mar 200420 Jul 2010Advanced Cardiovascular Systems, Inc.Biocompatible polyacrylate compositions for medical applications
US775888124 Mar 200520 Jul 2010Advanced Cardiovascular Systems, Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US776688425 May 20073 Ago 2010Advanced Cardiovascular Systems, Inc.Polymers of fluorinated monomers and hydrophilic monomers
US77723599 Sep 200810 Ago 2010Advanced Cardiovascular Systems, Inc.Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US777517826 May 200617 Ago 2010Advanced Cardiovascular Systems, Inc.Stent coating apparatus and method
US777692611 Dic 200217 Ago 2010Advanced Cardiovascular Systems, Inc.Biocompatible coating for implantable medical devices
US778551225 May 200431 Ago 2010Advanced Cardiovascular Systems, Inc.Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US778564725 Jul 200531 Ago 2010Advanced Cardiovascular Systems, Inc.Methods of providing antioxidants to a drug containing product
US77862499 Sep 200831 Ago 2010Advanced Cardiovascular Systems, Inc.Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US77947432 Sep 200514 Sep 2010Advanced Cardiovascular Systems, Inc.Polycationic peptide coatings and methods of making the same
US779546726 Abr 200514 Sep 2010Advanced Cardiovascular Systems, Inc.Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US780339417 Nov 200628 Sep 2010Advanced Cardiovascular Systems, Inc.Polycationic peptide hydrogel coatings for cardiovascular therapy
US780340626 Ago 200528 Sep 2010Advanced Cardiovascular Systems, Inc.Polycationic peptide coatings and methods of coating implantable medical devices
US78072105 Abr 20045 Oct 2010Advanced Cardiovascular Systems, Inc.Hemocompatible polymers on hydrophobic porous polymers
US780721127 May 20045 Oct 2010Advanced Cardiovascular Systems, Inc.Thermal treatment of an implantable medical device
US781380823 Nov 200512 Oct 2010Remon Medical Technologies LtdImplanted sensor system with optimized operational and sensing parameters
US782073230 Abr 200426 Oct 2010Advanced Cardiovascular Systems, Inc.Methods for modulating thermal and mechanical properties of coatings on implantable devices
US782353330 Jun 20052 Nov 2010Advanced Cardiovascular Systems, Inc.Stent fixture and method for reducing coating defects
US783326628 Nov 200716 Nov 2010Boston Scientific Scimed, Inc.Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US7837650 *30 Dic 200423 Nov 2010Advanced Cardiovascular Systems, Inc.Method and apparatus to prevent reperfusion injury
US784208327 Feb 200630 Nov 2010Innovational Holdings, Llc.Expandable medical device with improved spatial distribution
US785072714 Nov 200514 Dic 2010Innovational Holdings, LlcExpandable medical device for delivery of beneficial agent
US786754719 Dic 200511 Ene 2011Advanced Cardiovascular Systems, Inc.Selectively coating luminal surfaces of stents
US787506830 Sep 200325 Ene 2011Merit Medical Systems, Inc.Removable biliary stent
US787528626 Ago 200525 Ene 2011Advanced Cardiovascular Systems, Inc.Polycationic peptide coatings and methods of coating implantable medical devices
US789259230 Nov 200422 Feb 2011Advanced Cardiovascular Systems, Inc.Coating abluminal surfaces of stents and other implantable medical devices
US789691213 Abr 20041 Mar 2011Innovational Holdings, LlcExpandable medical device with S-shaped bridging elements
US790170323 Mar 20078 Mar 2011Advanced Cardiovascular Systems, Inc.Polycationic peptides for cardiovascular therapy
US7919075 *20 Mar 20025 Abr 2011Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US792275620 May 201012 Abr 2011Boston Scientific Scimed, Inc.Stent
US793168327 Jul 200726 Abr 2011Boston Scientific Scimed, Inc.Articles having ceramic coated surfaces
US79388552 Nov 200710 May 2011Boston Scientific Scimed, Inc.Deformable underlayer for stent
US794292611 Jul 200717 May 2011Boston Scientific Scimed, Inc.Endoprosthesis coating
US794814813 Oct 200924 May 2011Remon Medical Technologies Ltd.Piezoelectric transducer
US795119323 Jul 200831 May 2011Boston Scientific Scimed, Inc.Drug-eluting stent
US795526820 Jul 20077 Jun 2011Cardiac Pacemakers, Inc.Multiple sensor deployment
US795967120 Nov 200314 Jun 2011Merit Medical Systems, Inc.Differential covering and coating methods
US797689116 Dic 200512 Jul 2011Advanced Cardiovascular Systems, Inc.Abluminal stent coating apparatus and method of using focused acoustic energy
US797691523 May 200712 Jul 2011Boston Scientific Scimed, Inc.Endoprosthesis with select ceramic morphology
US798115024 Sep 200719 Jul 2011Boston Scientific Scimed, Inc.Endoprosthesis with coatings
US798525230 Jul 200826 Jul 2011Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US79854407 Sep 200526 Jul 2011Advanced Cardiovascular Systems, Inc.Method of using a mandrel to coat a stent
US79854414 May 200626 Jul 2011Yiwen TangPurification of polymers for coating applications
US79981929 May 200816 Ago 2011Boston Scientific Scimed, Inc.Endoprostheses
US800282113 Sep 200723 Ago 2011Boston Scientific Scimed, Inc.Bioerodible metallic ENDOPROSTHESES
US800282311 Jul 200723 Ago 2011Boston Scientific Scimed, Inc.Endoprosthesis coating
US80031564 May 200623 Ago 2011Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US800777530 Dic 200430 Ago 2011Advanced Cardiovascular Systems, Inc.Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US801714021 May 200713 Sep 2011Advanced Cardiovascular System, Inc.Drug-delivery stent formulations for restenosis and vulnerable plaque
US801723723 Jun 200613 Sep 2011Abbott Cardiovascular Systems, Inc.Nanoshells on polymers
US80216768 Jul 200520 Sep 2011Advanced Cardiovascular Systems, Inc.Functionalized chemically inert polymers for coatings
US80295542 Nov 20074 Oct 2011Boston Scientific Scimed, Inc.Stent with embedded material
US802981610 May 20074 Oct 2011Abbott Cardiovascular Systems Inc.Medical device coated with a coating containing elastin pentapeptide VGVPG
US80389911 Nov 200718 Oct 2011Abbott Cardiovascular Systems Inc.High-viscosity hyaluronic acid compositions to treat myocardial conditions
US804815012 Abr 20061 Nov 2011Boston Scientific Scimed, Inc.Endoprosthesis having a fiber meshwork disposed thereon
US804844125 Jun 20071 Nov 2011Abbott Cardiovascular Systems, Inc.Nanobead releasing medical devices
US804844815 Jun 20061 Nov 2011Abbott Cardiovascular Systems Inc.Nanoshells for drug delivery
US80527432 Ago 20078 Nov 2011Boston Scientific Scimed, Inc.Endoprosthesis with three-dimensional disintegration control
US805274413 Sep 20078 Nov 2011Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US805274513 Sep 20078 Nov 2011Boston Scientific Scimed, Inc.Endoprosthesis
US80529121 Oct 20048 Nov 2011Advanced Cardiovascular Systems, Inc.Temperature controlled crimping
US805753414 Sep 200715 Nov 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8062350 *21 Feb 200822 Nov 2011Abbott Cardiovascular Systems Inc.RGD peptide attached to bioabsorbable stents
US8062353 *12 Nov 200922 Nov 2011Advanced Cardiovascular Systems, Inc.Abluminal, multilayer coating constructs for drug-delivery stents
US806676311 May 201029 Nov 2011Boston Scientific Scimed, Inc.Drug-releasing stent with ceramic-containing layer
US806702315 Jul 200529 Nov 2011Advanced Cardiovascular Systems, Inc.Implantable medical devices incorporating plasma polymerized film layers and charged amino acids
US806702520 Mar 200729 Nov 2011Advanced Cardiovascular Systems, Inc.Nitric oxide generating medical devices
US80670545 Abr 200729 Nov 2011Boston Scientific Scimed, Inc.Stents with ceramic drug reservoir layer and methods of making and using the same
US80698144 May 20066 Dic 2011Advanced Cardiovascular Systems, Inc.Stent support devices
US807079727 Feb 20086 Dic 2011Boston Scientific Scimed, Inc.Medical device with a porous surface for delivery of a therapeutic agent
US80711564 Mar 20096 Dic 2011Boston Scientific Scimed, Inc.Endoprostheses
US808005527 Dic 200720 Dic 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US808806015 Nov 20063 Ene 2012Orbusneich Medical, Inc.Progenitor endothelial cell capturing with a drug eluting implantable medical device
US80890291 Feb 20063 Ene 2012Boston Scientific Scimed, Inc.Bioabsorbable metal medical device and method of manufacture
US810990425 Jun 20077 Feb 2012Abbott Cardiovascular Systems Inc.Drug delivery medical devices
US811021122 Sep 20047 Feb 2012Advanced Cardiovascular Systems, Inc.Medicated coatings for implantable medical devices including polyacrylates
US8114150 *14 Jun 200614 Feb 2012Advanced Cardiovascular Systems, Inc.RGD peptide attached to bioabsorbable stents
US81144663 Ene 200814 Feb 2012Boston Scientific Scimed, Inc.Methods of applying coating to the inside surface of a stent
US811886321 Feb 200821 Feb 2012Abbott Cardiovascular Systems Inc.RGD peptide attached to bioabsorbable stents
US812868914 Sep 20076 Mar 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis with biostable inorganic layers
US814753911 Dic 20073 Abr 2012Boston Scientific Scimed, Inc.Stent with a coating for delivering a therapeutic agent
US814776916 May 20073 Abr 2012Abbott Cardiovascular Systems Inc.Stent and delivery system with reduced chemical degradation
US817319926 Sep 20068 May 2012Advanced Cardiovascular Systems, Inc.40-O-(2-hydroxy)ethyl-rapamycin coated stent
US818762027 Mar 200629 May 2012Boston Scientific Scimed, Inc.Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US81876215 Jun 200629 May 2012Advanced Cardiovascular Systems, Inc.Methods and compositions for treating post-myocardial infarction damage
US819275221 Nov 20035 Jun 2012Advanced Cardiovascular Systems, Inc.Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US81927604 Dic 20065 Jun 2012Abbott Cardiovascular Systems Inc.Methods and compositions for treating tissue using silk proteins
US819787916 Ene 200712 Jun 2012Advanced Cardiovascular Systems, Inc.Method for selectively coating surfaces of a stent
US820643611 Nov 200926 Jun 2012Merit Medical Systems, Inc.Coated stent with geometry determinated functionality and method of making the same
US82166322 Nov 200710 Jul 2012Boston Scientific Scimed, Inc.Endoprosthesis coating
US822182230 Jul 200817 Jul 2012Boston Scientific Scimed, Inc.Medical device coating by laser cladding
US82319803 Dic 200931 Jul 2012Boston Scientific Scimed, Inc.Medical implants including iridium oxide
US823604610 Jun 20087 Ago 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US826261210 Nov 201011 Sep 2012Advanced Cardiovascular Systems, Inc.Apparatus to prevent reperfusion injury
US826798717 Sep 200918 Sep 2012Merit Medical Systems, Inc.Medical appliance delivery apparatus and method of use
US82679922 Mar 201018 Sep 2012Boston Scientific Scimed, Inc.Self-buffering medical implants
US827109317 Sep 200418 Sep 2012Cardiac Pacemakers, Inc.Systems and methods for deriving relative physiologic measurements using a backend computing system
US82817379 Mar 20049 Oct 2012Boston Scientific Scimed, Inc.Coated medical device and method for manufacturing the same
US828793724 Abr 200916 Oct 2012Boston Scientific Scimed, Inc.Endoprosthese
US829336715 Jul 201123 Oct 2012Advanced Cardiovascular Systems, Inc.Nanoshells on polymers
US829389030 Abr 200423 Oct 2012Advanced Cardiovascular Systems, Inc.Hyaluronic acid based copolymers
US829827712 Nov 200930 Oct 2012Merit Medical Systems, Inc.Medical appliance optical delivery and deployment apparatus and method
US830364321 May 20106 Nov 2012Remon Medical Technologies Ltd.Method and device for electrochemical formation of therapeutic species in vivo
US83036517 Sep 20016 Nov 2012Advanced Cardiovascular Systems, Inc.Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US830397223 Feb 20066 Nov 2012Advanced Cardiovascular Systems, Inc.Hydrogel bioscaffoldings and biomedical device coatings
US83040124 May 20066 Nov 2012Advanced Cardiovascular Systems, Inc.Method for drying a stent
US835394626 Ago 200915 Ene 2013Merit Medical Systems, Inc.Bifurcated medical appliance delivery apparatus and method
US835394910 Sep 200715 Ene 2013Boston Scientific Scimed, Inc.Medical devices with drug-eluting coating
US835739130 Jul 200422 Ene 2013Advanced Cardiovascular Systems, Inc.Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US837710728 Feb 201119 Feb 2013Advanced Cardiovascular Systems, Inc.Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US837749928 Feb 201119 Feb 2013Abbott Cardiovascular Systems Inc.Methods of forming Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US83828243 Oct 200826 Feb 2013Boston Scientific Scimed, Inc.Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US838315815 Abr 200326 Feb 2013Abbott Cardiovascular Systems Inc.Methods and compositions to treat myocardial conditions
US838904428 Feb 20115 Mar 2013Advanced Cardiovascular Systems, Inc.Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US843114927 Feb 200830 Abr 2013Boston Scientific Scimed, Inc.Coated medical devices for abluminal drug delivery
US843555013 Ago 20087 May 2013Abbot Cardiovascular Systems Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US844960317 Jun 200928 May 2013Boston Scientific Scimed, Inc.Endoprosthesis coating
US84499017 Mar 200628 May 2013Innovational Holdings, LlcImplantable medical device with beneficial agent concentration gradient
US846577215 May 201218 Jun 2013Abbott Cardiovascular Systems Inc.Methods and compositions for treating tissue using silk proteins
US846577315 May 201218 Jun 2013Abbott Cardiovascular Systems Inc.Methods and compositions for treating tissue using silk proteins
US846578918 Jul 201118 Jun 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US84860129 Ago 201216 Jul 2013Advanced Cardiovascular Systems, Inc.Apparatus to prevent reperfusion injury
US84863867 Abr 201016 Jul 2013Abbott Cardiovascular Systems Inc.Modified two-component gelation systems, methods of use and methods of manufacture
US84863877 Abr 201016 Jul 2013Abbott Cardiovascular Systems Inc.Modified two-component gelation systems, methods of use and methods of manufacture
US850068011 Ene 20086 Ago 2013Abbott Cardiovascular Systems Inc.Device and method for combining a treatment agent and a gel
US850661721 Jun 200213 Ago 2013Advanced Cardiovascular Systems, Inc.Micronized peptide coated stent
US851231130 Nov 200620 Ago 2013Bradley H. StraussAugmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions
US852125918 Feb 200427 Ago 2013Advanced Cardiovascular Systems, Inc.Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US8563025 *23 Ene 200622 Oct 2013Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US856876431 May 200629 Oct 2013Advanced Cardiovascular Systems, Inc.Methods of forming coating layers for medical devices utilizing flash vaporization
US857461525 May 20105 Nov 2013Boston Scientific Scimed, Inc.Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US858606929 Dic 200519 Nov 2013Abbott Cardiovascular Systems Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US858607527 Nov 201219 Nov 2013Abbott Cardiovascular Systems Inc.Coatings for implantable devices comprising poly(hydroxy-alkanoates) and diacid linkages
US859203620 Sep 201226 Nov 2013Abbott Cardiovascular Systems Inc.Nanoshells on polymers
US859621518 Jul 20113 Dic 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US859767313 Dic 20063 Dic 2013Advanced Cardiovascular Systems, Inc.Coating of fast absorption or dissolution
US860353014 Jun 200610 Dic 2013Abbott Cardiovascular Systems Inc.Nanoshell therapy
US860363423 Mar 200910 Dic 2013Abbott Cardiovascular Systems Inc.End-capped poly(ester amide) copolymers
US86086613 Mar 200417 Dic 2013Advanced Cardiovascular Systems, Inc.Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US860912329 Nov 200417 Dic 2013Advanced Cardiovascular Systems, Inc.Derivatized poly(ester amide) as a biobeneficial coating
US860912625 May 201217 Dic 2013Advanced Cardiovascular Systems, Inc.Methods and compositions for treating post-myocardial infarction damage
US861376431 Ene 200824 Dic 2013Abbott Cardiovascular Systems Inc.Method and apparatus for treating vulnerable plaque
US8628568 *8 Ene 201014 Ene 2014Abbott Cardiovascular Systems Inc.Stent with drug coating with variable release rate
US863706926 Jul 201228 Ene 2014Abbott Cardiovascular Systems Inc.Device and method for combining a treatment agent and a gel
US863711018 Jul 201128 Ene 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US864765518 Jun 201011 Feb 2014Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US8652194 *23 Mar 200618 Feb 2014Abbott Cardiovascular Systems Inc.Method and apparatus for treating vulnerable plaque
US866873222 Mar 201111 Mar 2014Boston Scientific Scimed, Inc.Surface treated bioerodible metal endoprostheses
US867333419 Sep 200718 Mar 2014Abbott Cardiovascular Systems Inc.Stent coatings comprising hydrophilic additives
US868543116 Mar 20041 Abr 2014Advanced Cardiovascular Systems, Inc.Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US87031675 Jun 200622 Abr 2014Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US87031698 Ago 200722 Abr 2014Abbott Cardiovascular Systems Inc.Implantable device having a coating comprising carrageenan and a biostable polymer
US871526526 Jul 20126 May 2014Abbott Cardiovascular Systems Inc.Device and method for combining a treatment agent and a gel
US871533921 Nov 20116 May 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US87397278 Oct 20123 Jun 2014Boston Scientific Scimed, Inc.Coated medical device and method for manufacturing the same
US874132617 Nov 20063 Jun 2014Abbott Cardiovascular Systems Inc.Modified two-component gelation systems, methods of use and methods of manufacture
US874137823 Dic 20043 Jun 2014Advanced Cardiovascular Systems, Inc.Methods of coating an implantable device
US874137918 Jul 20113 Jun 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US874738510 May 201210 Jun 2014Abbott Cardiovascular Systems Inc.Methods and compositions to treat myocardial conditions
US875880127 Nov 201224 Jun 2014Abbott Cardiocascular Systems Inc.Coatings for implantable devices comprising poly(hydroxy-alkanoates) and diacid linkages
US877134315 Jun 20078 Jul 2014Boston Scientific Scimed, Inc.Medical devices with selective titanium oxide coatings
US877801431 Mar 200415 Jul 2014Advanced Cardiovascular Systems, Inc.Coatings for preventing balloon damage to polymer coated stents
US877837529 Abr 200515 Jul 2014Advanced Cardiovascular Systems, Inc.Amorphous poly(D,L-lactide) coating
US87783769 Jun 200615 Jul 2014Advanced Cardiovascular Systems, Inc.Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US879565212 Nov 20075 Ago 2014Abbott Cardiovascular Systems Inc.Methods and compositions to treat myocardial conditions
US880834223 Abr 201319 Ago 2014Abbott Cardiovascular Systems Inc.Nanoshell therapy
US880872614 Sep 200719 Ago 2014Boston Scientific Scimed. Inc.Bioerodible endoprostheses and methods of making the same
US881527327 Jul 200726 Ago 2014Boston Scientific Scimed, Inc.Drug eluting medical devices having porous layers
US881527528 Jun 200626 Ago 2014Boston Scientific Scimed, Inc.Coatings for medical devices comprising a therapeutic agent and a metallic material
US88214737 Dic 20092 Sep 2014Abbott Cardiovascular Systems Inc.Methods and compositions to treat myocardial conditions
US882843319 Abr 20059 Sep 2014Advanced Cardiovascular Systems, Inc.Hydrogel bioscaffoldings and biomedical device coatings
US88284366 May 20139 Sep 2014Abbott Cardiovascular Systems Inc.Methods and compositions for treating tissue using silk proteins
US88406605 Ene 200623 Sep 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US886518931 Dic 201221 Oct 2014Abbott Cardiovascular Systems Inc.Poly(ester amide)-based drug delivery systems
US88712366 Jun 201328 Oct 2014Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US887188327 Jul 201028 Oct 2014Abbott Cardiovascular Systems Inc.Biocompatible coating for implantable medical devices
US89002926 Oct 20092 Dic 2014Boston Scientific Scimed, Inc.Coating for medical device having increased surface area
US892049117 Abr 200930 Dic 2014Boston Scientific Scimed, Inc.Medical devices having a coating of inorganic material
US893234623 Abr 200913 Ene 2015Boston Scientific Scimed, Inc.Medical devices having inorganic particle layers
US895632310 Dic 201217 Feb 2015Advanced Cardiovascular Systems, Inc.Apparatus to prevent reperfusion injury
US896158826 Sep 200624 Feb 2015Advanced Cardiovascular Systems, Inc.Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US89867266 Jun 201324 Mar 2015Abbott Cardiovascular Systems Inc.Biocompatible polyacrylate compositions for medical applications
US900567217 Ene 200814 Abr 2015Abbott Cardiovascular Systems Inc.Methods of modifying myocardial infarction expansion
US90288597 Jul 200612 May 2015Advanced Cardiovascular Systems, Inc.Phase-separated block copolymer coatings for implantable medical devices
US905615529 May 200716 Jun 2015Abbott Cardiovascular Systems Inc.Coatings having an elastic primer layer
US906700018 Nov 201330 Jun 2015Abbott Cardiovascular Systems Inc.End-capped poly(ester amide) copolymers
US908467115 Jul 201321 Jul 2015Advanced Cardiovascular Systems, Inc.Methods of forming a micronized peptide coated stent
US910169711 Abr 201411 Ago 2015Abbott Cardiovascular Systems Inc.Hyaluronic acid based copolymers
US911419819 Nov 200325 Ago 2015Advanced Cardiovascular Systems, Inc.Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US917516219 Sep 20073 Nov 2015Advanced Cardiovascular Systems, Inc.Methods for forming stent coatings comprising hydrophilic additives
US924200521 Ago 200626 Ene 2016Abbott Cardiovascular Systems Inc.Pro-healing agent formulation compositions, methods and treatments
US928440917 Jul 200815 Mar 2016Boston Scientific Scimed, Inc.Endoprosthesis having a non-fouling surface
US93395929 Abr 200717 May 2016Abbott Cardiovascular Systems Inc.Polymers of fluorinated monomers and hydrocarbon monomers
US936449822 Jun 200914 Jun 2016Abbott Cardiovascular Systems Inc.Heparin prodrugs and drug delivery stents formed therefrom
US937544522 Jun 200928 Jun 2016Abbott Cardiovascular Systems Inc.Heparin prodrugs and drug delivery stents formed therefrom
US952221730 Abr 200420 Dic 2016Orbusneich Medical, Inc.Medical device with coating for capturing genetically-altered cells and methods for using same
US953312724 Jul 20063 Ene 2017Abbott Cardiovascular Systems Inc.Methods for inhibiting reperfusion injury
US953941020 May 201310 Ene 2017Abbott Cardiovascular Systems Inc.Methods and compositions for treating post-cardial infarction damage
US956130927 May 20047 Feb 2017Advanced Cardiovascular Systems, Inc.Antifouling heparin coatings
US956135131 May 20067 Feb 2017Advanced Cardiovascular Systems, Inc.Drug delivery spiral coil construct
US95805589 Jun 200828 Feb 2017Abbott Cardiovascular Systems Inc.Polymers containing siloxane monomers
US968763020 May 201327 Jun 2017Abbott Cardiovascular Systems Inc.Methods and compositions for treating post-cardial infarction damage
US977593013 Abr 20153 Oct 2017Abbott Cardiovascular Systems Inc.Composition for modifying myocardial infarction expansion
US20020007209 *6 Mar 200117 Ene 2002Scheerder Ivan DeIntraluminar perforated radially expandable drug delivery prosthesis and a method for the production thereof
US20030130716 *4 Ene 200210 Jul 2003Scimed Life Systems,Inc.Non-compliant balloon with compliant top-layer to protect coated stents during expansion
US20030229392 *23 May 200311 Dic 2003Wong Samuel J.Drug eluted vascular graft
US20040148010 *23 Ene 200329 Jul 2004Rush Scott LyleCoated endovascular AAA device
US20040191215 *24 Mar 200430 Sep 2004Michael FroixCompositions for induction of a therapeutic response
US20040230225 *19 Nov 200318 Nov 2004Avi PennerMethod and device for electrochemical formation of therapeutic species in vivo
US20050015142 *9 Mar 200420 Ene 2005Michael AustinCoated medical device and method for manufacturing the same
US20050149171 *30 Dic 20037 Jul 2005Mccullagh OrlaCrimp and weld wire connection
US20050185061 *23 Feb 200425 Ago 2005Andy BakerSelf photographing camera system
US20050208100 *19 Mar 200422 Sep 2005Jan WeberMedical articles having regions with polyelectrolyte multilayer coatings for regulating drug release
US20050265958 *16 May 20051 Dic 2005West Jennifer LNitric oxide releasing compositions and associated methods
US20050271697 *7 Jun 20058 Dic 2005Conor Medsystems, Inc.Local delivery of growth factors for stem cell transplantation
US20050271700 *3 Jun 20048 Dic 2005Desnoyer Jessica RPoly(ester amide) coating composition for implantable devices
US20060002975 *26 Ago 20055 Ene 2006Conor Medsystems, Inc.Method and apparatus for reducing tissue damage after ischemic injury
US20060039950 *23 Ago 200423 Feb 2006Zhengrong ZhouMulti-functional biocompatible coatings for intravascular devices
US20060121089 *23 Ene 20068 Jun 2006Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US20060135943 *17 Nov 200522 Jun 2006Evgenia MandrusovMethod and apparatus for treating vulnerable plaque
US20060206191 *11 May 200614 Sep 2006Jan WeberNon-compliant balloon with compliant top-layer to protect coated stents during expansion
US20060217797 *10 Jun 200528 Sep 2006Wong Samuel JAsymmetric drug eluting hemodialysis graft
US20060265043 *24 Mar 200623 Nov 2006Evgenia MandrusovMethod and apparatus for treating vulnerable plaque
US20070043428 *9 Mar 200622 Feb 2007The University Of Tennessee Research FoundationBarrier stent and use thereof
US20070112417 *12 Ene 200717 May 2007Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US20070154555 *30 Nov 20065 Jul 2007Strauss Bradley HAugmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions
US20070269486 *4 Abr 200722 Nov 2007Conor Medsystems, Llc.Methods and Devices for Reducing Tissue Damage After Ischemic Injury
US20070293941 *14 Jun 200620 Dic 2007Gale David CRGD peptide attached to bioabsorbable stents
US20080017202 *24 Jul 200624 Ene 2008Advanced Cardiovascular Systems, Inc.Methods for inhibiting reperfusion injury
US20080125851 *31 Ene 200829 May 2008Deborah KilpatrickMethod and apparatus for treating vulnerable plaque
US20080147176 *21 Feb 200819 Jun 2008Gale David CRgd peptide attached to bioabsorbable stents
US20080172120 *12 Ene 200717 Jul 2008Calvin FennEndoprosthesis delivery systems and related methods
US20080213464 *3 Ene 20084 Sep 2008Boston Scientific Scimed, Inc.Methods of applying coating to the inside surface of a stent
US20080215139 *11 Dic 20074 Sep 2008Mcmorrow DavidStent with a coating for delivering a therapeutic agent
US20080262330 *30 Jun 200623 Oct 2008Reynolds Melissa MAnalyte Sensors and Compositions for Use Therein
US20080311172 *25 Abr 200818 Dic 2008Schapira Jay NProgrammed-release, nanostructured biological construct
US20090118819 *30 Jun 20067 May 2009Mc3, Inc.Nitric Oxide Coatings for Medical Devices
US20090163991 *19 Dic 200725 Jun 2009Boston Scientific Scimed, Inc.Stent
US20100028416 *12 Sep 20084 Feb 2010Nitto Denko CorporationDrug carriers
US20100068242 *15 Nov 200718 Mar 2010Cantrell Gary LMedical Devices for Localized Drug Delivery
US20100131046 *8 Ene 201027 May 2010Santos Veronica JStent with drug coating with variable release rate
US20100145437 *17 Feb 201010 Jun 2010Boston Scientific Scimed, Inc.Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface
US20100222868 *20 May 20102 Sep 2010Boston Scientific Scimed, Inc.Stent
US20100233237 *21 May 201016 Sep 2010Avi PennerMethod and device for electrochemical formation of therapeutic species in vivo
US20100303882 *27 May 20092 Dic 2010Mallinckrodt Inc.Medical Devices for Localized Drug Delivery
US20110151104 *28 Feb 201123 Jun 2011Advanced Cardiovascular Systems, Inc.Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US20110153004 *28 Feb 201123 Jun 2011Advanced Cardiovascular Systems, Inc.Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US20110190873 *8 Abr 20114 Ago 2011Boston Scientific Scimed, Inc.Stent
US20110200660 *28 Feb 201118 Ago 2011Advanced Cardiovascular Systems, Inc.Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US20150190555 *17 Jul 20139 Jul 2015South Dakota Board Of RegentsMethods, Systems, and Devices Relating to Directional Eluting Implantable Medical Devices
USRE457447 Nov 201313 Oct 2015Abbott Cardiovascular Systems Inc.Temperature controlled crimping
CN103379882B *20 Dic 201016 Dic 2015哥德堡移植技术公司可移除式支架和生产方法
CN103635159A *9 May 201212 Mar 2014帕尔玛兹科学公司Implantable medical device having enhanced endothelial migration features and methods of making same
EP1732469A2 *4 Mar 200520 Dic 2006Conor Medsystems, Inc.Bioresorbable stent with beneficial agent reservoirs
EP1732469A4 *4 Mar 200517 Dic 2008Conor Medsystems IncBioresorbable stent with beneficial agent reservoirs
EP1737377A2 *17 Feb 20053 Ene 2007Boston Scientific LimitedCoated medical device and method for manufacturing the same
EP1737377A4 *17 Feb 20052 Dic 2009Boston Scient LtdCoated medical device and method for manufacturing the same
EP2305323A3 *15 Nov 200713 Abr 2011Boston Scientific LimitedStent with differential timing of abluminal and luminal release of a therapeutic agent
WO2005091834A217 Feb 20056 Oct 2005Boston Scientific LimitedCoated medical device and method for manufacturing the same
WO2005102222A24 Mar 20053 Nov 2005Conor Medsystems, Inc.Bioresorbable stent with beneficial agent reservoirs
WO2005112954A1 *16 May 20051 Dic 2005William Marsh Rice UniversityNitric oxide releasing compositions and associated methods
WO2006058434A12 Dic 20058 Jun 2006Strauss Bradley HAugmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions
WO2006112932A3 *15 Feb 200629 Mar 2007Advanced Cardiovascular SystemCoatings for implantable medical devices containing attractants for endothelial cells
WO2007097887A2 *30 Ene 200730 Ago 2007Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices containing attractants for endothelial cells
WO2007097887A3 *30 Ene 200718 Oct 2007Advanced Cardiovascular SystemCoatings for implantable medical devices containing attractants for endothelial cells
WO2007146001A2 *5 Jun 200721 Dic 2007Abbott Cardiovascular Systems Inc.Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
WO2007146001A3 *5 Jun 20077 Feb 2008Abbott Cardiovascular SystemsCoatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
WO2008063539A3 *15 Nov 200714 May 2009Boston Scient LtdStent with differential timing of abluminal and luminal release of a therapeutic agent
WO2008088537A2 *11 Dic 200724 Jul 2008Boston Scientific LimitedStent with a coating for delivering a therapeutic agent
WO2008088537A3 *11 Dic 20077 May 2009Boston Scient LtdStent with a coating for delivering a therapeutic agent
WO2010064222A227 Nov 200910 Jun 2010University College Cork, National University Of Ireland, CorkIgf1 for myocardial repair
WO2011019401A3 *12 Ago 201016 Jun 2011Duke UniversityCell coated implantable device
Clasificaciones
Clasificación de EE.UU.623/1.42
Clasificación internacionalA61F2/06, A61L31/16, A61F2/00, A61F2/90
Clasificación cooperativaA61F2250/0068, A61L2300/61, A61L31/16, A61L2300/414, A61F2002/91533, A61F2/91, A61L2300/602, A61L2300/45, A61L2300/412, A61L2300/416, A61F2/915
Clasificación europeaA61F2/91, A61F2/915, A61L31/16
Eventos legales
FechaCódigoEventoDescripción
30 Abr 2001ASAssignment
Owner name: ADVANCED CARDIOVASCULAR SYSTEMS, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MANDRUSOV, EVGENIA;CONSIGNY, PAUL;HOSSAINY, SYED F.A.;AND OTHERS;REEL/FRAME:011798/0481;SIGNING DATES FROM 20010426 TO 20010430
16 Mar 2004CCCertificate of correction
5 Mar 2007FPAYFee payment
Year of fee payment: 4
23 May 2011FPAYFee payment
Year of fee payment: 8
26 May 2015FPAYFee payment
Year of fee payment: 12